New COVID-19 Clinical Trials Funded
The first, ATTRACT, is in collaboration with Vicore Pharma, whom we have worked with for over 10 years on developing novel approaches for pulmonary fibrosis. The drug, VP01 (Compound 21; C21) is hoped to recalibrate the renin-angiotensin- system towards repair rather than inflammation. This should indirectly help our research into pulmonary fibrosis too.
The second study, COVASE, is a collaboration with Veni Papayannopoulos and Veronique Brilaut at The Francis Crick Institute, to investigate an approved nebulised recombinant human deoxyribonuclease I (Dornase alfa) to reduce hyperinflammation from neutrophil extracellular traps in the lungs of hospitalised participants with COVID-19.
ATTRACT is open to recruitment and COVASE will open in the next two weeks.
Here’s the LifeArc press release with more info: https://www.lifearc.org/funding/covid-19-funding/